[go: up one dir, main page]

OA11594A - Hydroxy pipecolate hydroxamic acid derivatives as MMP inhibitors. - Google Patents

Hydroxy pipecolate hydroxamic acid derivatives as MMP inhibitors. Download PDF

Info

Publication number
OA11594A
OA11594A OA1200100035A OA1200100035A OA11594A OA 11594 A OA11594 A OA 11594A OA 1200100035 A OA1200100035 A OA 1200100035A OA 1200100035 A OA1200100035 A OA 1200100035A OA 11594 A OA11594 A OA 11594A
Authority
OA
OAPI
Prior art keywords
hydroxy
alkyl
piperidine
compound according
benzenesulfonyl
Prior art date
Application number
OA1200100035A
Other languages
English (en)
Inventor
Louis Stanley Chupak
Michael Anthony Letavic
Kim Francis Mclure
Mark Carl Noe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11594A publication Critical patent/OA11594A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
OA1200100035A 1998-08-12 1999-08-05 Hydroxy pipecolate hydroxamic acid derivatives as MMP inhibitors. OA11594A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9623298P 1998-08-12 1998-08-12

Publications (1)

Publication Number Publication Date
OA11594A true OA11594A (en) 2004-07-11

Family

ID=22256467

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100035A OA11594A (en) 1998-08-12 1999-08-05 Hydroxy pipecolate hydroxamic acid derivatives as MMP inhibitors.

Country Status (43)

Country Link
US (2) US6329397B1 (de)
EP (1) EP1104403B1 (de)
JP (1) JP2002522528A (de)
KR (1) KR20010085374A (de)
CN (1) CN1316995A (de)
AP (1) AP2001002070A0 (de)
AR (1) AR019241A1 (de)
AT (1) ATE325791T1 (de)
AU (1) AU766366B2 (de)
BG (1) BG105323A (de)
BR (1) BR9912909A (de)
CA (1) CA2340202C (de)
CZ (1) CZ2001484A3 (de)
DE (1) DE69931266T2 (de)
DZ (1) DZ2870A1 (de)
EA (1) EA200100126A1 (de)
EE (1) EE200100086A (de)
ES (1) ES2263279T3 (de)
GE (1) GEP20033117B (de)
GT (1) GT199900131A (de)
HK (1) HK1040242A1 (de)
HN (1) HN1999000131A (de)
HR (1) HRP20010098A2 (de)
HU (1) HUP0103452A3 (de)
ID (1) ID27840A (de)
IL (1) IL141030A0 (de)
IS (1) IS5813A (de)
MA (1) MA26675A1 (de)
NO (1) NO20010686L (de)
NZ (1) NZ509296A (de)
OA (1) OA11594A (de)
PA (1) PA8479201A1 (de)
PE (1) PE20000951A1 (de)
PL (1) PL346041A1 (de)
SK (1) SK1872001A3 (de)
SV (1) SV1999000123A (de)
TN (1) TNSN99156A1 (de)
TR (1) TR200100474T2 (de)
UA (1) UA59453C2 (de)
UY (1) UY25993A1 (de)
WO (1) WO2000009485A1 (de)
YU (1) YU5201A (de)
ZA (1) ZA200101042B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
AU754719B2 (en) * 1998-08-31 2002-11-21 Merck & Co., Inc. Method of treating neurodegenerative diseases
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (de) * 1999-08-12 2001-03-07 Pfizer Products Inc. Selektive Inhibitoren von Aggrecanase zur Behandlung von Osteoarthritis
EP1138680A1 (de) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituierte Sulfonylhydroxamsäuren mit MMP inhibierender Wirkung
JP2001322977A (ja) * 2000-05-12 2001-11-20 Kotobuki Seiyaku Kk ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) * 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
MXPA03004920A (es) 2001-02-14 2003-09-05 Warner Lambert Co Pirimidinas inhibidoras de metaloproteinasas de matriz.
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
CA2494249A1 (en) * 2002-06-26 2004-01-08 Koichi Yokota Novel azasugar derivative and drug containing the same as the active ingredient
WO2004007025A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
CA2489722A1 (en) * 2002-07-17 2004-01-22 William Howard Roark Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014880A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
EP1553949B1 (de) 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
CA2494014A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
AU2006256442A1 (en) * 2005-03-22 2006-12-14 Bellus Health (Innodia) Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
ES2357682T3 (es) 2008-03-25 2011-04-28 Affectis Pharmaceuticals Ag Antagonistas de p2x7r novedosos y su utilización.
SG175232A1 (en) 2009-04-14 2011-12-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
DE202016007195U1 (de) 2016-11-16 2017-11-17 Bernhard Kohler Strombegrenzende Schalteinrichtung
US20220008401A1 (en) * 2019-01-29 2022-01-13 Darsha Llc Compositions and methods for treating pulmonary disease with matrix metalloproteinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519751T2 (de) * 1995-04-20 2001-04-19 Pfizer Inc., New York Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
EP1095936B1 (de) * 1995-12-08 2004-11-24 Agouron Pharmaceuticals, Inc. Zwischenprodukte zur Herstellung von Metallproteinasehemmern
SK25099A3 (en) * 1996-08-28 2000-02-14 Procter & Gamble Substituted cyclic amine metalloprotease inhibitors
CN1113862C (zh) * 1997-02-03 2003-07-09 辉瑞产品公司 芳基磺酰氨基异羟肟酸衍生物
AU722784B2 (en) * 1997-02-11 2000-08-10 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
GEP20033117B (en) 2003-11-25
NO20010686D0 (no) 2001-02-09
IL141030A0 (en) 2002-02-10
YU5201A (sh) 2003-07-07
ID27840A (id) 2001-04-26
MA26675A1 (fr) 2004-12-20
DE69931266T2 (de) 2007-02-15
EA200100126A1 (ru) 2001-08-27
CZ2001484A3 (cs) 2002-05-15
BR9912909A (pt) 2001-05-08
SV1999000123A (es) 2000-07-06
KR20010085374A (ko) 2001-09-07
ATE325791T1 (de) 2006-06-15
AR019241A1 (es) 2001-12-26
UY25993A1 (es) 2000-03-31
EP1104403A1 (de) 2001-06-06
NO20010686L (no) 2001-04-09
IS5813A (is) 2001-01-16
JP2002522528A (ja) 2002-07-23
PE20000951A1 (es) 2000-09-27
TR200100474T2 (tr) 2001-06-21
AU4924799A (en) 2000-03-06
CN1316995A (zh) 2001-10-10
BG105323A (en) 2001-10-31
AP2001002070A0 (en) 2001-03-31
PA8479201A1 (es) 2000-09-29
HN1999000131A (es) 2000-03-24
US20030008901A1 (en) 2003-01-09
UA59453C2 (uk) 2003-09-15
HRP20010098A2 (en) 2002-02-28
HUP0103452A3 (en) 2002-10-28
SK1872001A3 (en) 2002-08-06
NZ509296A (en) 2003-10-31
CA2340202A1 (en) 2000-02-24
PL346041A1 (en) 2002-01-14
AU766366B2 (en) 2003-10-16
EP1104403B1 (de) 2006-05-10
ZA200101042B (en) 2002-10-07
WO2000009485A1 (en) 2000-02-24
DZ2870A1 (fr) 2003-12-15
US6329397B1 (en) 2001-12-11
HUP0103452A2 (hu) 2002-04-29
GT199900131A (es) 2001-02-02
EE200100086A (et) 2002-08-15
TNSN99156A1 (fr) 2005-11-10
ES2263279T3 (es) 2006-12-01
DE69931266D1 (en) 2006-06-14
HK1040242A1 (zh) 2002-05-31
CA2340202C (en) 2006-02-07

Similar Documents

Publication Publication Date Title
OA11594A (en) Hydroxy pipecolate hydroxamic acid derivatives as MMP inhibitors.
CA2327758C (en) (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
US6608104B2 (en) Gem substituted hydroxamic acids
EP1104412B1 (de) Tace inhibitoren
CA2268484C (en) Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
US6114361A (en) 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
CA2303498C (en) Dioxocyclopentyl hydroxamic acids
US5612353A (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
BG104919A (bg) Двуциклени производни на хидроксамова киселина
US6458822B2 (en) 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
US6387901B1 (en) Alkyne containing metalloproteinase inhibitors
MXPA99003372A (en) Derivatives of ciclobutil acid-ariloxiarilsulfonilamino hidroxam
MXPA99010152A (en) Hydroxyamide derivatives of 5-oxo-pirrolidine-2-carboxyl acid
MXPA00003181A (en) Dioxocyclopentyl hydroxamic acids